Interim data from the REDEEM-1 Phase 1/2a study reported earlier this year showed a 100% complete response rate among six efficacy-evaluable patients with relapsed/refractory multiple myeloma, per IMWG criteria, with a favorable safety profile. The program targets both BCMA and CD19 with a parallel dual-target CAR architecture and is generating additional readouts that will be presented at the ISCT Annual Meeting in Dublin on May 6–9.
The core development is Tempest Therapeutics’ plan to showcase updated clinical data for TPST-2003, its autologous dual-targeting CD19/BCMA CAR-T candidate, including progress from REDEEM-1 in multiple myeloma and supplemental studies across the same construct. REDEEM-1 is being run by partner Novatim Immune Therapeutics at eight sites in China, with a target enrollment of 29 patients including high-risk cytogenetics and extramedullary disease. Two additional Novatim-led trials are in flight: an investigator-initiated rrMM study and a Phase 1 in POEMS syndrome. Tempest holds exclusive rights to TPST-2003 outside China, India, Turkey, and Russia.
Strategically, this is a classic speed-to-signal play in a crowded category dominated by BCMA-directed CAR-Ts. The differentiator is dual targeting intended to address tumor heterogeneity and antigen escape, while the operational lever is an Asia-first clinical path that compresses timelines and cost. The tension is obvious: the bar for efficacy and durability is high after cilta-cel’s deep responses and ongoing label expansion, and any entrant must show more than parity. A clean early safety profile and activity in extramedullary disease could carve a niche, but the dataset is still small and regionally generated. Translating China-based manufacturing, analytics, and clinical outcomes into a U.S./EU program will require a disciplined comparability package, harmonized release testing, and likely a dedicated ex-China IND with bridging cohorts.
For sites and sponsors, a CD19/BCMA construct that maintains simple operational footprints would be attractive, but dual-target engineering can complicate CMC and supply reliability, which directly impacts scheduling, vein-to-vein times, and bed utilization. If TPST-2003 truly performs in extramedullary disease—a population that routinely underperforms on single-antigen BCMA products—enrollment criteria could broaden, increasing referral volumes and demand for leukapheresis capacity. CROs and platform vendors should note the likely need for global tech transfer, chain-of-identity/chain-of-custody integrations, and regional release testing strategies as Tempest moves beyond China. Regulators will scrutinize consistency of product attributes across manufacturing sites and the robustness of durability endpoints; payers will eventually look for superiority or clear niche positioning to justify another high-cost cell therapy.
The next turning points are durability and safety at scale. Watch for 6–12 month DOR, PFS, MRD negativity rates, and granular CRS/ICANS incidence and management—particularly in patients with extramedullary disease and high-risk cytogenetics. Also important is clarity on Tempest’s ex-China development plan: timing of a U.S./EU IND, source and readiness of a non-China manufacturing network, and the design of any bridging or global Phase 2 intended to support registration. Competitive dynamics are shifting as approved BCMA CAR-Ts push earlier lines and as other dual-target constructs mature; any delay risks ceding the extramedullary differentiation argument to peers.
If the ISCT update confirms depth of response beyond the initial six patients and begins to show durability with manageable toxicity, TPST-2003 earns a closer look as a potential niche entrant with broader ambitions. Absent that, the program will face the familiar cell therapy trap: promising biology offset by operational friction and an unforgiving comparator set.
Source link: https://www.globenewswire.com/news-release/2026/04/29/3283678/0/en/Tempest-to-Advance-Dual-Targeting-CAR-T-Platform-with-Clinical-Update-at-ISCT-2026-Annual-Meeting.html
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
